TITLE

Saxagliptin Tablets (Onglyza)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
September 2009
SOURCE
Internal Medicine Alert;9/29/2009, Vol. 31 Issue 18, p141
SOURCE TYPE
Periodical
DOC. TYPE
Product Review
ABSTRACT
The article evaluates the diabetes mellitus treatment drug Saxaglipitin, Dipeptidyl peptidase-4 (DPP-4) by Bristol-Myers Squibb Co.
ACCESSION #
44453976

 

Related Articles

  • New molecular entity.  // Formulary;Sep2009, Vol. 44 Issue 9, p261 

    The article evaluates the Onglyza Saxaglipitin drug from Bristol-Myers Squibb Co. and Astrazeneca for the treatment of type 2 diabetes mellitus.

  • FDA actions.  // Infectious Disease Alert;Aug2012 Pharmacology Watch, p2 

    The article reports on the opinions issued by the U.S. Food and Drug Administration (FDA) on oral novel anticoagulants rivaroxaban from Janssen and apixaban from Bristol-Myers Squibb.

  • Eliquis aims to amp up its sales push. Weinstein, Deborah // Medical Marketing & Media;Jun2014, Vol. 49 Issue 6, p13 

    The article reports on the plans of pharmaceutical partners Bristol-Myers Squibb Co. and Pfizer Inc. for an amplified push of the sale for blood thinner Eliquis, driven by its first-quarter earnings.

  • Active Pharmaceutical Watch.  // Chemical Market Reporter;11/4/2002, Vol. 262 Issue 16, p9 

    Presents news briefs about the pharmaceutical industry as of November 4, 2002. Clinical trials of the oral anticoagulant Exanta; Net income of Bristol-Myers Squibb Co.; Deal between GlaxoSmithKline PLC and Exelixis Inc.

  • NACDS Foundation scholarship award.  // Drug Store News;6/6/2005, Vol. 27 Issue 8, p30 

    The article reports that at the 2005 National Association of Chain Drug Stores (NACDS) annual meeting held in Palm Beach, Florida, the NACDS Foundation Pharmacy Partners Scholarship Program and Bristol-Myers Squibb Co. awarded a $20,000 donation to Shenandoah University.

  • EU delays new cancer drug. Investor's Business Daily // Investors Business Daily;3/30/2015, pA02 

    The article reports on the move of European Medicines Agency, a European Union (EU) agency, which delayed the melanoma and lung cancer-fighting drug Nivolumab manufactured by Bristol-Myers Squibb Co. despite its approval in the U.S.

  • Dutonin.  // Royal Society of Medicine: Medicines;2002, p219 

    This article presents information on the drug Dutonin from Bristol-Myers Squibb. This is a proprietary, prescription-only preparation of the atypical nefazodone hydrochloride, which is used to treat depressive illness. It is available as tablets.

  • Plavix.  // Royal Society of Medicine: Medicines;2002, p443 

    The article presents information on plavix which is a proprietary, prescription-only preparation of the drug clopidogrel manufactured by Bristol-Myers Squibb and Sanofi-Synthelabo. It can be used to prevent thrombosis, and is available as tablets.

  • TOP STORIES.  // MondayMorning;5/3/2010, Vol. 18 Issue 17, p1 

    The article offers news briefs related to healthcare industry in the U.S. Biotechnology companies worldwide reduce research spending while revenue increased. Bristol-Myers Squibb Co. increases profits by 14% due to the higher sales of its blood-clot pill Plavix and HIV medicines. Discounts on...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics